Immunological monitoring and clinical trials of biological response modifiers.
Kopp
W C
WC
Program Resources Inc., National Cancer Institute, Frederick Cancer Research and Development Center, MD, USA.
Holmlund
J T
JT
Urba
W J
WJ
D000818:Animals; D002986:Clinical Trials as Topic; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007372:Interferons / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use / Q000633:toxicity; D007377:Interleukin-3 / Q000627:therapeutic use; D016173:Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D008550:Melatonin / Q000627:therapeutic use; D015166:Monitoring, Immunologic; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use
D007155:Immunologic Factors; D007376:Interleukin-2; D007377:Interleukin-3; D014409:Tumor Necrosis Factor-alpha; D016173:Macrophage Colony-Stimulating Factor; D007372:Interferons; D008550:Melatonin